Protembis said today it closed a $10 million Series A round, joined by cardiovascular device-focused Abiomed (NSDQ:ABMD), to support its embolic cerebral protection device.
The round was joined by Abiomed, Aachen and Mönchengladbach GmbH’s Seed Fonds III and a number of family offices and angel investors, the Aachen, Germany-based company said.
“Patient safety should always be our top priority. We see great potential in Protembis’ technology to make TAVI neurologically safer and thus enable TAVI to be used in an even larger patient population,” Abiomed chief technology officer Dr. Thorsten Siess said in a prepared statement.
Protembis is developing the ProtEmbo embolic cerebral protection device designed to minimize the risk of embolic cerebral lesions during minimally invasive cardiovascular interventions. The system consists of a filter device designed to be introduced into the aortic arch to prevent embolic particles from migrating into the brain.
“Literally every TAVI intervention leads to particle migration to the brain” co-managing director & co-founder Karl von Mangoldt said in a prepared release.
“Recent clinical studies have shown that up to 9 percent of TAVI patients suffer a stroke” co-managing director & co-founder Conrad Rasmus said in a press release.
Last July, Protembis said it plans to collaborate with the German Accelerator Life Sciences program as it looks to expand into the US and accelerate the clinical development plans for its cerebral embolic protection device.
